期刊
EXPERIMENTAL NEUROLOGY
卷 283, 期 -, 页码 452-475出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.expneurol.2016.04.002
关键词
Myelin vacuolation; Demyelination; Leukodystrophy; Multiple sclerosis; Toxin; Deficiency
资金
- NIH [NS32361, NS055816]
- NMSS [RG-1501-02876]
- Boespflug Foundation
- MS Hope for a Cure
- Oscar Rennebohm Foundation
Remyelination is a major therapeutic goal in human myelin disorders, serving to restore function to demyelinated axons and providing neuroprotection. The target disorders that might be amenable to the promotion of this repair process are diverse and increasing in number. They range primarily from those of genetic, inflammatory to toxic origin. In order to apply remyelinating strategies to these disorders, it is essential to know whether the myelin damage results from a primary attack on myelin or the oligodendrocyte or both, and whether indeed these lead to myelin breakdown and demyelination. In some disorders, myelin sheath abnormalities are prominent but demyelination does not occur. This review explores the range of human and animal disorders where myelin pathology exists and focusses on defining the myelin changes in each and their cause, to help define whether they are targets for myelin repair therapy. (C) 2016 Elsevier Inc All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据